Organogenesis Holdings Inc.

NasdaqCM:ORGO Rapporto sulle azioni

Cap. di mercato: US$354.0m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Organogenesis Holdings Gestione

Gestione criteri di controllo 2/4

Organogenesis Holdings' Il CEO è Gary Gillheeney, nominato in Jan2014, e ha un mandato di 10.58 anni. la retribuzione annua totale è $ 6.24M, composta da 14.6% di stipendio e 85.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.63% delle azioni della società, per un valore di $ 2.15M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.9 anni e 3.8 anni.

Informazioni chiave

Gary Gillheeney

Amministratore delegato

US$6.2m

Compenso totale

Percentuale dello stipendio del CEO14.6%
Mandato del CEO10.6yrs
Proprietà del CEO0.6%
Durata media del management6.9yrs
Durata media del Consiglio di amministrazione3.8yrs

Aggiornamenti recenti sulla gestione

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gary Gillheeney rispetto agli utili di Organogenesis Holdings?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

Compensazione vs Mercato: La retribuzione totale di Gary ($USD 6.24M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: La retribuzione di Gary è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Gary Gillheeney (69 yo)

10.6yrs

Mandato

US$6,244,671

Compensazione

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Gary Gillheeney
President10.6yrsUS$6.24m0.63%
$ 2.2m
David Francisco
Chief Financial Officer3.5yrsUS$1.63m0.048%
$ 170.5k
Patrick Bilbo
Chief Operating Officer6.9yrsUS$2.16m0.26%
$ 926.7k
Lori Freedman
Chief Administrative & Legal Officer7.6yrsUS$1.99m0.063%
$ 224.1k
Brian Grow
Chief Commercial Officer6.9yrsUS$1.92m0.078%
$ 277.2k
William Kolb
Secretaryno dataNessun datoNessun dato
Robert Cavorsi
Vice President of Strategy3.6yrsNessun dato0.11%
$ 373.2k

6.9yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di ORGO è esperto e expertise (durata media dell'incarico 6.9 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Gary Gillheeney
President5.7yrsUS$6.24m0.63%
$ 2.2m
Glenn Nussdorf
Director21.6yrsNessun dato11.29%
$ 40.0m
Alan Ades
Director21.6yrsNessun dato11.5%
$ 40.7m
Arthur Leibowitz
Lead Independent Director5.7yrsUS$291.46k0.10%
$ 364.7k
Robert Ades
Director3.8yrsNessun datoNessun dato
Jon Giacomin
Independent Director3.3yrsUS$265.00k0.068%
$ 239.9k
Michele Korfin
Independent Director2.3yrsUS$226.98k0.068%
$ 239.4k
Prathyusha Duraibabu
Independent Director2.8yrsUS$240.00k0.071%
$ 250.6k
David Erani
Director3.8yrsNessun datoNessun dato
Michael Driscoll
Independent Director2.5yrsUS$230.52kNessun dato
Gilberto Quintero
Independent Director2.3yrsUS$226.98k0.068%
$ 239.4k

3.8yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ORGO sono considerati esperti (durata media dell'incarico 3.8 anni).